Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Paschon DE"'
Autor:
Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Casorati G, Greenberg PD, Holmes MC, Gregory PD, Naldini L, BONDANZA , ATTILIO, CICERI, FABIO, BORDIGNON, CLAUDIO, BONINI , MARIA CHIARA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10495::3e0e4c0b490ec224b3025a3bbf51fd3e
Autor:
Genovese P, Provasi E, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, Bonini C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10495::6e538e097af34c8100320a2aa144500d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Kniha
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Maurilio Ponzoni, Giulia Casorati, Andreas Reik, Philip D. Greenberg, Barbara Camisa, Luigi Naldini, Michael C. Holmes, Angelo Lombardo, Fabio Ciceri, Claudio Bordignon, Pei-Qi Liu, Pietro Genovese, Philip D. Gregory, Chiara Bonini, Lei Zhang, J. Kuball, David Paschon, Elena Provasi, Victoria Chu, Zulma Magnani, Attilio Bondanza
Publikováno v:
Blood. 118:667-667
Abstract 667 Transfer of high-avidity T-cell receptor (TCR) genes isolated from rare tumor-specific lymphocytes into polyclonal CD8+ T cells is an attractive strategy for targeted cancer immunotherapy. However, the successful implementation of this a
Autor:
Miller JC; Sangamo Therapeutics, Inc., Richmond, CA, USA., Patil DP; Sangamo Therapeutics, Inc., Richmond, CA, USA., Xia DF; Sangamo Therapeutics, Inc., Richmond, CA, USA., Paine CB; Sangamo Therapeutics, Inc., Richmond, CA, USA., Fauser F; Sangamo Therapeutics, Inc., Richmond, CA, USA., Richards HW; Sangamo Therapeutics, Inc., Richmond, CA, USA., Shivak DA; Sangamo Therapeutics, Inc., Richmond, CA, USA., Bendaña YR; Sangamo Therapeutics, Inc., Richmond, CA, USA., Hinkley SJ; Sangamo Therapeutics, Inc., Richmond, CA, USA., Scarlott NA; Sangamo Therapeutics, Inc., Richmond, CA, USA., Lam SC; Sangamo Therapeutics, Inc., Richmond, CA, USA., Reik A; Sangamo Therapeutics, Inc., Richmond, CA, USA., Zhou Y; Sangamo Therapeutics, Inc., Richmond, CA, USA., Paschon DE; Sangamo Therapeutics, Inc., Richmond, CA, USA., Li P; Sangamo Therapeutics, Inc., Richmond, CA, USA., Wangzor T; Sangamo Therapeutics, Inc., Richmond, CA, USA., Lee G; Sangamo Therapeutics, Inc., Richmond, CA, USA., Zhang L; Sangamo Therapeutics, Inc., Richmond, CA, USA., Rebar EJ; Sangamo Therapeutics, Inc., Richmond, CA, USA. erebar@sangamo.com.
Publikováno v:
Nature biotechnology [Nat Biotechnol] 2019 Aug; Vol. 37 (8), pp. 945-952. Date of Electronic Publication: 2019 Jul 29.
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease.
Autor:
Zeitler B; Sangamo Therapeutics, Inc., Richmond, CA, USA. bzeitler@sangamo.com., Froelich S; Sangamo Therapeutics, Inc., Richmond, CA, USA., Marlen K; Sangamo Therapeutics, Inc., Richmond, CA, USA., Shivak DA; Sangamo Therapeutics, Inc., Richmond, CA, USA., Yu Q; Sangamo Therapeutics, Inc., Richmond, CA, USA., Li D; Sangamo Therapeutics, Inc., Richmond, CA, USA., Pearl JR; Sangamo Therapeutics, Inc., Richmond, CA, USA., Miller JC; Sangamo Therapeutics, Inc., Richmond, CA, USA., Zhang L; Sangamo Therapeutics, Inc., Richmond, CA, USA., Paschon DE; Sangamo Therapeutics, Inc., Richmond, CA, USA., Hinkley SJ; Sangamo Therapeutics, Inc., Richmond, CA, USA., Ankoudinova I; Sangamo Therapeutics, Inc., Richmond, CA, USA., Lam S; Sangamo Therapeutics, Inc., Richmond, CA, USA., Guschin D; Sangamo Therapeutics, Inc., Richmond, CA, USA.; Laboratory of Intracellular Signalling, Moscow Institute of Physics and Technology, Dolgoprudnyi, Russian Federation., Kopan L; Sangamo Therapeutics, Inc., Richmond, CA, USA., Cherone JM; Sangamo Therapeutics, Inc., Richmond, CA, USA., Nguyen HB; Sangamo Therapeutics, Inc., Richmond, CA, USA., Qiao G; Sangamo Therapeutics, Inc., Richmond, CA, USA., Ataei Y; Sangamo Therapeutics, Inc., Richmond, CA, USA., Mendel MC; Sangamo Therapeutics, Inc., Richmond, CA, USA., Amora R; Sangamo Therapeutics, Inc., Richmond, CA, USA., Surosky R; Sangamo Therapeutics, Inc., Richmond, CA, USA., Laganiere J; Sangamo Therapeutics, Inc., Richmond, CA, USA.; Medical Affairs and Innovation, Hema-Quebec, Quebec City, Quebec, Canada., Vu BJ; Sangamo Therapeutics, Inc., Richmond, CA, USA., Narayanan A; Sangamo Therapeutics, Inc., Richmond, CA, USA., Sedaghat Y; Evotec AG, Hamburg, Germany., Tillack K; Evotec AG, Hamburg, Germany., Thiede C; Evotec AG, Hamburg, Germany., Gärtner A; Evotec AG, Hamburg, Germany., Kwak S; CHDI Management/CHDI Foundation, Los Angeles, CA, USA., Bard J; CHDI Management/CHDI Foundation, Los Angeles, CA, USA., Mrzljak L; CHDI Management/CHDI Foundation, Los Angeles, CA, USA., Park L; CHDI Management/CHDI Foundation, Los Angeles, CA, USA., Heikkinen T; Charles River Discovery Services, Kuopio, Finland., Lehtimäki KK; Charles River Discovery Services, Kuopio, Finland., Svedberg MM; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Häggkvist J; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Tari L; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Tóth M; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Varrone A; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Halldin C; Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Kudwa AE; Psychogenics, Inc., Paramus, NJ, USA., Ramboz S; Psychogenics, Inc., Paramus, NJ, USA., Day M; Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Kondapalli J; Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Surmeier DJ; Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Urnov FD; Sangamo Therapeutics, Inc., Richmond, CA, USA.; Innovative Genomics Institute, Berkeley, CA, USA., Gregory PD; Sangamo Therapeutics, Inc., Richmond, CA, USA., Rebar EJ; Sangamo Therapeutics, Inc., Richmond, CA, USA., Muñoz-Sanjuán I; CHDI Management/CHDI Foundation, Los Angeles, CA, USA. ignacio.munoz@chdifoundation.org., Zhang HS; Sangamo Therapeutics, Inc., Richmond, CA, USA.; Applied StemCell, Inc., Milpitas, CA, USA.
Publikováno v:
Nature medicine [Nat Med] 2019 Jul; Vol. 25 (7), pp. 1131-1142. Date of Electronic Publication: 2019 Jul 01.
Autor:
Llewellyn GN; Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., Seclén E; Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., Wietgrefe S; Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Liu S; School of Pharmacy, University of Southern California, Los Angeles, California, USA., Chateau M; Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA., Pei H; School of Pharmacy, University of Southern California, Los Angeles, California, USA., Perkey K; Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Marsden MD; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.; Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, USA., Hinkley SJ; Sangamo Therapeutics, Inc., Richmond, California, USA., Paschon DE; Sangamo Therapeutics, Inc., Richmond, California, USA., Holmes MC; Sangamo Therapeutics, Inc., Richmond, California, USA., Zack JA; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.; Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, USA., Louie SG; School of Pharmacy, University of Southern California, Los Angeles, California, USA., Haase AT; Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Cannon PM; Department of Molecular Microbiology and Immunology, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA pcannon@usc.edu.
Publikováno v:
Journal of virology [J Virol] 2019 May 01; Vol. 93 (10). Date of Electronic Publication: 2019 May 01 (Print Publication: 2019).
Autor:
Conway A; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA. Electronic address: aconway@sangamo.com., Mendel M; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., Kim K; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., McGovern K; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., Boyko A; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., Zhang L; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., Miller JC; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., DeKelver RC; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., Paschon DE; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., Mui BL; Acuitas Therapeutics, 6190 Agronomy Rd., Suite 402, Vancouver, BC, Canada., Lin PJC; Acuitas Therapeutics, 6190 Agronomy Rd., Suite 402, Vancouver, BC, Canada., Tam YK; Acuitas Therapeutics, 6190 Agronomy Rd., Suite 402, Vancouver, BC, Canada., Barbosa C; Acuitas Therapeutics, 6190 Agronomy Rd., Suite 402, Vancouver, BC, Canada., Redelmeier T; Acuitas Therapeutics, 6190 Agronomy Rd., Suite 402, Vancouver, BC, Canada., Holmes MC; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA., Lee G; Sangamo Therapeutics, 501 Canal Blvd., Suite A, Richmond, CA 94804, USA.
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2019 Apr 10; Vol. 27 (4), pp. 866-877. Date of Electronic Publication: 2019 Mar 07.
Autor:
Paschon DE; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Lussier S; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Wangzor T; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Xia DF; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Li PW; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Hinkley SJ; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Scarlott NA; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Lam SC; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Waite AJ; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Truong LN; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Gandhi N; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Kadam BN; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Patil DP; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Shivak DA; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Lee GK; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Holmes MC; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Zhang L; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Miller JC; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA., Rebar EJ; Sangamo Therapeutics, Inc., 501 Canal Boulevard, Suite A100, Richmond, California, 94804, USA. erebar@sangamo.com.
Publikováno v:
Nature communications [Nat Commun] 2019 Mar 08; Vol. 10 (1), pp. 1133. Date of Electronic Publication: 2019 Mar 08.